Novartis Ag (NVS) Cash & Equivalents Growth (3y) (2012 - 2026)
Novartis Ag (NVS) Cash & Equivalents Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.21% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -9.15% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 6.56% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -11.22% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -4.72% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -25.80% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -17.71% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -28.16% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 1.97% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -5.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.22% |
| Mar 31, 2026 | -16.94% |
| Dec 31, 2025 | 15.01% |
| Jun 30, 2025 | 321.32% |
| Mar 31, 2025 | -20.10% |
| Dec 31, 2024 | -2.61% |
| Sep 30, 2024 | 194.72% |
| Jun 30, 2024 | 996.73% |
| Mar 31, 2024 | 35.56% |
| Dec 31, 2023 | 11.51% |
| Sep 30, 2023 | 119.16% |
| Jun 30, 2023 | 425.63% |
| Mar 31, 2023 | 38.39% |
| Dec 31, 2022 | -12.22% |
| Jun 30, 2022 | -79.27% |
| Mar 31, 2022 | 26.72% |
| Dec 31, 2021 | -2.22% |
| Jun 30, 2021 | -26.00% |
| Mar 31, 2021 | -13.20% |
| Dec 31, 2020 | 2.92% |